Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

XPhyto: Proof of Concept for Mescalin Synthesis

It’s become a much talked-about story on both sides of the Atlantic. XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTCQB: XPHYF) has earned considerable media coverage in recent months due to its expansion into the development of psychedelic d...
Marc Davis | June 9, 2021 |

A Life Sciences Project Accelerator Kicks into High Gear

XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTC: XPHYF) has been a hot story lately, especially in Germany, due to its recent commercialization of a super-fast PCR test kit for definitively diagnosing COVID-19 infections in point-of-care settings. The company rec...
Marc Davis | May 10, 2021 |

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. Clinical-stage biotechnology...
Streetwise Reports | July 2, 2020 |

Curis' Shares Take Off as FDA Clears IND Application for Monoclonal Anti-VISTA Antibody

Curis Inc. shares are up more than 130% and established a new 52-week high price after reporting that the FDA cleared the company's IND Application for CI-8993, its monoclonal anti-VISTA antibody. Biotechnology company Curis Inc. (CRIS:NASDAQ) , which concentrates...
Streetwise Reports | June 11, 2020 |

Aurora, Bayer, XPhyto - scalable growth markets with potential

Health is the most precious good in the life of a human being. The preservation and improvement of the quality of life is a large business area. Investors around the globe have the opportunity to participate in many different areas of research and development of products and t...
Mario Hose | June 8, 2020 |

Micro-Cap Pharma Moving Ahead with Plans for Phase 3 US Trial of a Repurposed Drug for Covid-19

Revive Therapeutics is focused on infectious diseases as well as treatments using psilocybin-based formulations. Revive Therapeutics Ltd. (RVV:TSX.V; RVVTF:OTCMKTS) , a company that focuses on repurposing drugs for infectious diseases and rare disorders, is prepari...
Streetwise Reports | June 4, 2020 |

Arbutus Biopharma Trades 25% Higher on Phase 1 Hepatitis B Results

Shares of Arbutus Biopharma traded higher after the company reported significant and continuous reduction in HBsAg in 12 chronic hepatitis B subjects using 60 mg dosage of its AB-729 drug. Clinical-stage biopharmaceutical company Arbutus Biopharma Corp. (ABUS:NASD...
Streetwise Reports | May 20, 2020 |

Moderna Shares Rise 25% on Positive Phase 1 Coronavirus Vaccine Trial Data

Shares of Moderna Inc. traded higher, setting a new 52-week high price, after the firm reported positive interim results in its Phase 1 study of mRNA Vaccine (mRNA-1273) against SARS-CoV-2. Clinical-stage biotechnology company Moderna Inc. (MRNA:NASDAQ) , which fo...
Streetwise Reports | May 19, 2020 |

Chimerix Shares Rise 50% as FDA Gives 'Go Ahead' for Phase 2/3 ALI Study in COVID-19 Patients

Shares of Chimerix Inc. traded higher after the company reported it has received U.S. FDA clearance to initiate a Phase 2/3 Study of dociparstat sodium in acute lung injury for patients afflicted with severe COVID-19. Biopharmaceutical company Chimerix Inc....
Streetwise Reports | April 29, 2020 |

Avadel Shares Rise and Shine on Positive Phase 3 Narcolepsy Study Findings

Avadel Pharmaceuticals' shares traded 25% higher reaching a new 52-week high price after the company reported positive topline results from its Pivotal Phase 3 REST-ON trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. ...
Streetwise Reports | April 28, 2020 |
1 2 3